Statistically Significant Results For TC-5619 On Measures Of Cognitive Dysfunction In Schizophrenia And Negative Symptoms Of Schizophrenia

Targacept, Inc. (NASDAQ: TRGT) today announced the presentation of data from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia at the International Congress on Schizophrenia Research (ICOSR) in Colorado Springs, Colorado. Results presented at ICOSR showed statistically significant superiority of TC-5619 over placebo on secondary efficacy outcome measures assessing improvement on cognitive dysfunction in schizophrenia and negative symptoms of schizophrenia...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/8GjXEmSrWRY/221844.php

sport sport medical sport news